Industry News

Dexcom Announces Development Agreement with Lilly to Integrate Dexcom CGM into Connected Diabetes Ecosystem

You are here

Tuesday, November 21, 2017

Two leaders to combine tools aimed at reducing complexity and burden while improving outcomes in diabetes management

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, today announced a development agreement with Eli Lilly and Company (NYSE: LLY) to include Dexcom CGM into Lilly's Connected Diabetes Ecosystem. The companies expect to combine Lilly's smart insulin delivery devices and Dexcom CGM to improve the future of diabetes management.

"Lilly's Connected Diabetes Ecosystem promises to drive a significant step forward in diabetes management. As technology converges in our industry, we believe that connected systems will become the standard of care over time," said Kevin Sayer, President and CEO of Dexcom. "By combining devices, drugs and technology, we can deliver solutions that adapt to each person's unique needs in managing their diabetes while also providing compelling advancements for both physicians and payers."

Through the Connected Diabetes Ecosystem, the companies aim to provide a comprehensive solution to people with diabetes. Devices such as CGM, smart-pens and insulin pumps, drugs, apps and other analytical tools will be aimed at improving outcomes. Clinical trials are expected to begin by the end of 2017.

"The Connected Diabetes Ecosystem relies not only on Lilly's core diabetes expertise, but also the strength of our key partners such as Dexcom," said Enrique Conterno, president, Lilly Diabetes and Lilly USA. "Dexcom will be an important collaborator in our mission to improve outcomes and reduce the daily burden for people with diabetes."

About DexCom, Inc. (NASDAQ: DXCM)

DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked Dexcom highest in customer satisfaction and loyalty. For more information, visit www.dexcom.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171121005676/en/

DexCom Media Contact
Melissa Katz, 215-514-0957
mkatz@stonyhillcomms.com
or
DexCom Investor Contact
Steven Pacelli, 858-200-0200
spacelli@dexcom.com

Source: DexCom, Inc.

News Provided by Acquire Media

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.